Read by QxMD icon Read


Freddy Caldera, Elizabeth Ann Misch, Sumona Saha, Arnold Wald, Youqi Zhang, Jeffrey Hubers, Bryant Megna, Dana Ley, Mark Reichelderfer, Mary S Hayney
BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends using the immunization record and not serologic testing to determine immunity against measles and rubella in the general population, due to potential false negatives. However, it is unknown whether the immune response is less durable among patients who are immunosuppressed. AIMS: The primary aim of this study was to evaluate sustained vaccine-induced measles, mumps, and rubella (MMR) antibody concentrations in immunosuppressed patients with inflammatory bowel disease (IBD)...
October 13, 2018: Digestive Diseases and Sciences
Yuzhe Huang, Jian Guo, Shuangying Gui
The current treatments used in inflammatory bowel disease (IBD) therapy have significant side effects. Thus, it is very necessary to position and release TNF-α siRNA in inflamed tissues. Here, we demonstrate that poly(lactic-co-glycolic acid) can pack TNF-α siRNA efficiently into nanoparticles (NPs), and galactosylated chitosan (GC) can be grafted onto the NP surface, improving the RAW 264.7 macrophage-targeting kinetics of the NPs in vitro. Next, we orally administered GC-modified NPs loaded with TNF-α siRNA to C57BL/6 mice treated with 3% dextran sodium sulfate (DSS) to investigate their use in the treatment of colitis...
October 10, 2018: European Journal of Pharmaceutical Sciences
A Hünerwadel, S Fagagnini, G Rogler, C Lutz, S U Jaeger, C Mamie, B Weder, P A Ruiz, M Hausmann
Intestinal fibrosis is thought to be a consequence of excessive tissue repair, and constitutes a common problem in patients with Crohn's disease (CD). While fibrosis seems to require inflammation as a prerequisite it is unclear whether the severity or persistence of inflammation influences the degree of fibrosis. Our aim was to investigate the role of sustained inflammation in fibrogenesis. For the initiation of fibrosis in vivo the models of Il10-/- spontaneous colitis, dextran sodium sulfate (DSS)-induced chronic colitis and heterotopic transplantation were used...
October 12, 2018: Scientific Reports
Shahar Bar Yehuda, Rachel Axlerod, Ori Toker, Nir Zigman, Iris Goren, Vered Mourad, Natan Lederman, Nurit Cohen, Eran Matz, Doron Dushnitzky, Matan Gavish, Nirit Borovsky, Doron Schwarts, Iris Dotan, Dan Turner
Introduction: There are conflicting data on the association between inflammatory bowel diseases (IBD) and autoimmunity disorders. The aim of this study was to explore this association including the effect of medications on this association. Methods: We utilized health administrative data collected by 3 of 4 Israel's Health Maintenance Organizations (HMO) covering 52% of the population of Israel. We explored the prevalence of the following autoimmune disorders: Insulin Dependent Diabetes Mellitus (IDDM), psoriasis, Sjögren syndrome, celiac, systemic lupus erythematosus (SLE), primary sclerosis cholangitis (PSC) and autoimmune thyroiditis, among all IBD patients versus non-IBD controls...
October 9, 2018: Journal of Crohn's & Colitis
Wei He, Yongmin Li, Mengyang Liu, Haiyang Yu, Qian Chen, Yue Chen, Jingya Ruan, Zhijuan Ding, Yi Zhang, Tao Wang
Inflammatory bowel disease (IBD) is a serious digestive system disease, for which the clinical therapeutic choices remain limited. Dried fruits of Citrus aurantium L. (CAL) are a traditional medicine used for regulation of the digestive system. The aim of this study was to identify the regulatory effects of CAL on IBD and to clarify the mechanism of the active compounds. In trinitrobenzene sulfonic acid-induced IBD rats, 125 to 500 mg/kg of oral CAL significantly alleviated weight loss and diarrhea, decreased colitis inflammatory cell infiltration, and inhibited pro-inflammatory cytokine production...
October 7, 2018: International Journal of Molecular Sciences
Kimberly N Weaver, Martin Gregory, Gaurav Syal, Patrick Hoversten, Stephen Bradley Hicks, Devin Patel, George Christophi, Poonam Beniwal-Patel, Kim L Isaacs, Laura Raffals, Parakkal Deepak, Hans H Herfarth, Edward L Barnes
Background: Crohn's disease (CD) of the pouch and chronic pouchitis occur in approximately 10% of patients after ileal pouch-anal anastomosis (IPAA) for refractory ulcerative colitis (UC) or UC-related dysplasia. The efficacy of anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been reported for the treatment of CD of the pouch and chronic pouchitis, but little is known regarding the use of ustekinumab in these settings. Our primary aim was to evaluate the efficacy of ustekinumab for these conditions...
October 5, 2018: Inflammatory Bowel Diseases
Sena Tolu, Aylin Rezvani, Nurbanu Hindioglu, Merve Calkin Korkmaz
Tumor necrosis factor (TNF)-α is a cytokine that plays a well-established, key role as a central mediator of inflammation and immune regulation. TNF-α and its receptors are suggested to play a critical role in a number of chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), juvenile chronic arthritis, and inflammatory bowel disease (IBD). TNF-α inhibitors are currently used in the treatment of these diseases. We report a 29-year-old male with AS who developed Crohn's disease while taking etanercept...
October 6, 2018: Rheumatology International
Sabri Sudirman, Yuan-Hua Hsu, Jia-Ling He, Zwe-Ling Kong
Inflammatory bowel disease (IBD) is a known medical burden in most developed countries and a significant cause of morbidity. The IBD label includes Crohn's disease (CD) and ulcerative colitis (UC). Pharmacological and surgical intervention are the two main management approaches for IBD. Some drugs have been developed for IBD therapy, but accessibility is limited due to high costs. Furthermore, these agents have demonstrated inactivity over long-term treatment courses. Therefore, an urgent need is present for new treatment options that are safe, able to sustain clinical remission, and improve mucosal gut healing...
2018: PloS One
Katsuyoshi Matsuoka, Shunsuke Hamada, Mikiko Shimizu, Kosaku Nanki, Shinta Mizuno, Hiroki Kiyohara, Mari Arai, Shinya Sugimoto, Yasushi Iwao, Haruhiko Ogata, Tadakazu Hisamatsu, Makoto Naganuma, Takanori Kanai, Mayumi Mochizuki, Masayuki Hashiguchi
Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown...
2018: PloS One
Karla F Castro-Ochoa, Hilda Vargas-Robles, Sandra Chánez-Paredes, Alfonso Felipe-López, Rodolfo I Cabrera-Silva, Mineko Shibayama, Abigail Betanzos, Porfirio Nava, Erwin A Galinski, Michael Schnoor
BACKGROUND: Inflammatory bowel diseases (IBD) are multifactorial disorders affecting millions of people worldwide with alarmingly increasing incidences every year. Dysfunction of the intestinal epithelial barrier is associated with IBD pathogenesis, and therapies include anti-inflammatory drugs that enhance intestinal barrier function. However, these drugs often have adverse side effects thus warranting the search for alternatives. Compatible solutes such as bacterial ectoines stabilize cell membranes and proteins...
September 29, 2018: Digestive Diseases and Sciences
Martin H Gregory, Andrew McKinnon, Dustin Stwalley, K J Hippensteel, Edward V Loftus, Matthew A Ciorba, Margaret A Olsen, Parakkal Deepak
Background and Aims: There is a paucity of data on the safety of joint replacement surgery in patients with inflammatory bowel disease (IBD), including those on tumor necrosis factor-alpha inhibitors (anti-TNF). We explored the risk of serious infections in this population. Methods: A retrospective case-control study (2006-2014) was performed using the MarketScan® Database. All patients 18-64 years with an International Classification of Diseases code for IBD and an IBD-specific medication, with ≥6 months of enrollment prior to hip, knee or shoulder replacement surgery, were included...
September 26, 2018: Journal of Crohn's & Colitis
Bram Verstockt, Séverine Vermeire, Gert Van Assche, Marc Ferrante
Entamoeba histolytica colitis can mimic Crohn's disease. However, a fulminant infection can be life-threatening, especially after exposure to systemic steroids. We present a case of the patient who was initially diagnosed with ileocolonic Crohn's disease, but developed a hepatic E histolytica abscess while undergoing anti-TNF therapy. After revision of the initial diagnostic biopsies, the diagnosis was questioned and E histolytica was confirmed using PCR and histopathology. As intestinal amoebiasis is the most common form of amoebic infection, care should be taken in case of refractory IBD or at initial diagnosis in patients who travelled to endemic areas...
September 26, 2018: Scandinavian Journal of Gastroenterology
Dana Duricova, Eva Dvorakova, Ondrej Hradsky, Katarina Mitrova, Marianna Durilova, Jana Kozeluhova, Pavel Kohout, Kristyna Zarubova, Jiri Bronsky, Nora Hradska, Eva Bronska, Miroslava Adamcova, Nadezda Machkova, Veronika Hruba, Martin Bortlik, Martin Lukas, Karin Malickova, Milan Lukas
Background: Evidence of the impact of in utero exposure to anti-tumor necrosis factor (TNF)-alpha on long-term childhood development is limited. The aim was to assess the impact of in utero exposure to anti-TNF-alpha due to mothers' inflammatory bowel disease (IBD) on long-term postnatal development of exposed children. Methods: We included consecutive children (≥12 months of age) born to mothers with IBD (2007-2016) treated with anti-TNF-alpha during pregnancy in 3 centers in the Czech Republic...
September 20, 2018: Inflammatory Bowel Diseases
Rhonda M Brand, Nabanita Biswas, Aaron Siegel, Ashley Myerski, Jarret Engstrom, E Jeffrey Metter, Randall E Brand, Ross D Cranston, Ian McGowan
BACKGROUND: There are limited data on the immunological responsiveness of healthy intestinal tissue when it is cultured and stimulated ex vivo. Such an ex vivo model has the potential to be a valuable tool in understanding disease pathogenesis and as a preclinical tool for the assessment of candidate therapeutic agents used to treat inflammatory bowel disease (IBD). AIM: We undertook a comprehensive study to evaluate ex vivo immunological responses of intestinal tissue and isolated mucosal mononuclear cells (MMC) to a broad range of stimuli...
September 12, 2018: Journal of Immunological Methods
Webber Chan, Hang Hock Shim, Siew Chien Ng, Jeffrey Liu, Christian Inglis, Kay Greveson, Brandon Baraty, Craig Haifer, Rupert W L Leong
Background: With increasing use of biological therapies and immunosuppressive agents, patients with inflammatory bowel disease[IBD] have improved clinical outcome and international travel in this group is becoming common. Adequate pre-travel advice is important. We aim to determine the proportion of gastroenterologists who provided pre-travel advice, and to assess their management strategies for patients on biological therapies visiting tuberculosis[TB]-endemic areas. Methods: A 57-question survey was distributed to IBD physicians in 23 countries...
September 11, 2018: Journal of Crohn's & Colitis
Xiong Chen, Rui Liu, Xiaoming Liu, Canxia Xu, Xiaoyan Wang
Aim: To investigate the role of Coxsackie-adenovirus receptor (CAR) in inflammatory bowel disease (IBD). Background: CAR, a type I transmembrane protein with functions in virus attachment, has been shown to be associated with epithelial tight junctions (TJs) and mediates cell adhesion, implying its potential roles in the pathogenesis of IBD. Methods and Materials: To determine the effect of CAR in IBD using QPCR and Western blotting to determine the expression of CAD in TNF- α induced NCM460 and SW480 cells and IBD tissues compared to control groups...
2018: BioMed Research International
Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos
The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies...
August 28, 2018: World Journal of Gastroenterology: WJG
Sang Won Park, Suhrid Banskota, Pallavi Gurung, You Jin Jin, Han-Eol Kang, Chhabi Lal Chaudhary, Sang Yeul Lee, Byeong-Seon Jeong, Jung-Ae Kim, Tae-Gyu Nam
Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract with complex pathogenesis. Here, we synthesized 6-heteroarylamino analogues to inhibit TNF-α-induced adhesion of monocytes to colon epithelial cells which are implicated in the initial inflammation process of IBD. The best analogue, 16a , showed IC50 = 0.29 μM, which is about five orders of magnitude better than that of 5-aminosalicylic acid (5-ASA), a positive control. Oral administration of 6f and 16a dramatically ameliorated 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation in rat...
August 1, 2018: MedChemComm
K-J Kim, J-M Park, J-S Lee, Y S Kim, N Kangwan, Y-M Han, E A Kang, J M An, Y K Park, K-B Hahm
Repeated bouts of ulcerative colitis featured troublesome course of inflammatory bowel disease leading to fatal colitis-associated cancer, which is strongly associated with oxidative stress and sustained inflammation. Since oligonol, low molecular weighted polyphenol extracted from fruit lychee, showed antioxidative and anti-inflammatory actions, we hypothesized that oligonolcan prevent relapse of colitis. We compared oligonol with current gold standard therapeutics, sulfasalazine in preventive efficacy of relapse...
June 2018: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
Iulia Elena Filipescu, Leonardo Leonardi, Laura Menchetti, Gabriella Guelfi, Giovanna Traina, Patrizia Casagrande-Proietti, Federica Piro, Alda Quattrone, Olimpia Barbato, Gabriele Brecchia
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder for which the current medical therapy is not completely effective. Bovine colostrum (BC) is a biological fluid rich in bioactive molecules that may have beneficial effects on several gastrointestinal disorders. The objectives of this study were to assess the preventive effects of BC supplementation in a mouse model of 2,4,6 trinitrobenzene sulfonic acid (TNBS)-induced colitis using a multidisciplinary approach. Specifically, the following parameters were evaluated: (i) disease activity index (DAI), (ii) histological score, (iii) expression levels of TLR4, anti- and pro-inflammatory cytokines, and (iv) count of some bacterial species of the intestinal microbiota...
2018: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"